Additional Supporting Information may be found in the online version of this article.

ijc28091-sup-0001-suppfig1.tif1543KSupplemental Figure 1. miR-137 expression in two further neuroblastoma cohorts
ijc28091-sup-0002-suppfig2.tif1820KSupplemental Figure 2. Survival rates of neuroblastoma patient cohorts
ijc28091-sup-0003-suppfig3.tif1897KSupplemental Figure 3. Cell cycle analysis of neuroblastoma cells upon miR-137 re-expression and KDM1A knockdown
ijc28091-sup-0004-suppfig4.tif2200KSuppplemental Figure 4. Two further siRNAs against KDM1A phenocopy the miR-137 reexpression phenotype
ijc28091-sup-0005-supptab1.tif1312KSupplemental Table 1. Summary of patient and tumor characterists for the three neuroblastoma cohorts used in this study
ijc28091-sup-0006-supptab2.tif1817KSupplemental Table 2. Summary of patient and tumor characterists for the miRNA transcriptome sequencinq data that was re-analyzed for this study
ijc28091-sup-0007-supptab3.tif1620KSupplemental Table 3. Summary of all cell cycle data collected by FACS analysis

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.